Method and compositions for the treatment or amelioration of female sexual dysfunction

ABSTRACT

The present invention provide a method of treating sexual dysfunction in a female, including the vasculogenic symptoms of delayed vaginal engorgement, diminished vaginal lubrication, pain or discomfort with intercourse (dyspareunia), diminished vaginal sensation, diminished vaginal orgasm, diminished clitoral sensation or diminished clitoral orgasm, or of combating vaginal pain by stimulating peripheral pelvic nerve release of nitric oxide (NO). The method comprises administering to a female in need of such treatment a therapeutically effective amount of a compound which acts on a mid-brain pathway to increase blood flow to the ilio-hypogastric-pudendal artery bed and stimulate the release of nitric oxide (NO) from peripheral NANC nerve cells. The preferred compound for the method of this invention is apomorphine or one of its pharmaceutically acceptable salts, esters, or pro-drugs. Alternatively, the apomorphine is co-administered with an apomorphine-potentiating amount of an androgen, preferably testosterone either prior to, or concomitantly with, the administration of the apomorphine.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of co-pending application,Ser. No. 09/102,987 filed Jun. 22, 1998 which is a continuation-in-partof application Ser. No. 08/546,498 filed Oct. 20, 1995, now U.S. Pat.No. 5,770,606 which, in turn, is a continuation-in-part of applicationSer. No. 08/231,250 filed on Apr. 22, 1994, now abandoned.

FIELD OF THE INVENTION

The present invention relates to methods of diagnosing, treating, orameliorating sexual dysfunction in female mammals, including methods oftreating delayed vaginal engorgement, diminished vaginal lubrication,pain or discomfort with intercourse (dyspareunia), diminished vaginalsensation, diminished vaginal orgasm, diminished clitoral sensation ordiminished clitoral orgasm, or of treating vaginal pain by stimulatingperipheral pelvic nerve release of nitric oxide (NO). The treatmentmethods of the present invention include the improvement in a female ofthe physiological state associated with sexual activity includingappropriate vaginal lubrication, vaginal sensation, vaginal orgasm, orclitoral sensation, but in whom one of the above-mentioned abnormalconditions may not be present.

BACKGROUND OF THE INVENTION

Sexual response in mammals is mediated by a balanced interplay betweenthe sympathetic and parasympathetic nervous systems. Vasocongestion, orerectile tumescence in both the male and female, is largely mediated byparasympathetic (cholinergic) outflow, whereas orgasm is predominantlysympathetic (adrenergic).

Sexuality in human females encompasses multiple components includingphysiological, psychological, social and emotional factors. However, thefirst phase of the female sexual response is mediated by a combinationof vasocongestive and neuromuscular events which include increasedclitoral length and diameter, as well as increased vaginal lubrication,wall engorgement and increased luminal diameter.

The clitoris is the homologue of the penis, arising from theembryological genital tubercle. As a result, the two organs have similarstructural and arousal response mechanisms. The clitoris consists of acylindrical, erectile organ composed of three parts: the outermost glansor head, the middle corpus or body, and the innermost crura. The body ofthe clitoris consists of paired corpora cavernosa of about 2.5 cm inlength and lacks a corpus spongiosum. During sexual arousal, blood flowto the corpora cavernosa of the clitoris cause their enlargement andtumescence.

The clitoris plays a major role during sexual activity in that itinduces local autonomic and somatic reflexes causing vaginalvasocongestion, engorgement, and subsequent transduction, lubricatingthe introital canal making the sexual act easier, more comfortable, andmore pleasurable.

Vaginal wall engorgement enables a process of plasma transduction tooccur, allowing a flow through the epithelium and onto the vaginalsurface. Plasma transduction results from the rising pressure in thevaginal capillary bed during the sexual arousal state. In addition,there is an increase in vaginal length and luminal diameter, especiallyin the distal ⅔ of the vaginal canal.

The vaginal canal is lubricated primarily from a transudate originatingfrom the subepithelial vascular bed passively transported through theinterepithelial spaces sometimes referred to as intercellular channels.Additional moistening during intercourse comes from secretion of thepaired greater vestibular or Bartholin's glands.

These events depend upon sufficient blood flow to these organs duringsexual arousal, and a physiologic disorder which impairs this bloodflow, resulting in female vasculogenic sexual dysfunction, canultimately lead to or exacerbate a pre-existing psychological condition.

The arterial supply to the vagina is derived from an extensive networkof branching vessels surrounding it from all sides. The anterior branchof the internal iliac artery continually bifurcates as it descendsthrough the pelvis with a series of the newly generated vessel, eachsupplying the vagina to some degree. After giving off an obturatorartery branch, the umbilical and the middle rectal arteries diverge offto supply a superior and inferior vesical artery, respectively. Betweenthe umbilical and the midrectal branches there is generation of auterine artery which further bifurcates to give the vaginal artery. Theinternal pudendal and accessory pudendal artery also sends a branch.Finally the common clitoral artery sends a branch to the vaginalmuscularis.

The main arterial supply to the clitoris is from theilio-hypogastric-pudendal arterial bed. The internal pudendal artery isthe last anterior branch of the internal iliac artery. Distally, theinternal pudendal artery traverses Alcock's canal, a position of theobturator fascia and lies on the inner side in supposition to theischiopubic ramis. In this latter location, the artery is susceptible toblunt perineal trauma. The internal pudendal artery terminates as itsupples the inferior rectal and perineal artery, which supplies thelabia. The common clitoral artery continues to the clitoris. This arterybifurcates into a dorsal clitoral artery and a cavernosal clitoralartery.

Based upon animal research, it has been found that central nervoussystem areas primarily implicated in sexual arousal include the medialpre-optic, anterior hypothalamic region and related limbic-hippocampalstructures of the brain.

Female sexual dysfunction which has its origin in abnormal arterialcirculation into the vagina or clitoris during sexual stimulation may beconsidered a disorder of arousal. This vasculogenic female sexualdysfunction may include such clinical symptoms as delayed vaginalengorgement, diminished vaginal lubrication, pain or discomfort withintercourse (dyspareunia), diminished vaginal sensation, diminishedvaginal orgasm, diminished clitoral sensation or diminished clitoralorgasm.

Moreover, traumatic injury to the ilio-hypogastric-pudendal arterial bedfrom pelvic fractures or blunt perineal trauma may also result indiminished vaginal/clitoral blood flow following sexual stimulation andfall into the vasculogenic dysfunction category.

Vaginal pain may derive from a general vaginal hyperalgesia orsensitivity to stimulation associated with coitus (dyspareunia) whenthere has been sufficient genital engorgement and lubrication.

Treatment of female sexual dysfunction is gradually evolving as moreclinical and basic science studies are dedicated to the investigation ofthis medical problem. Female sexual complaints are not all psychologicalin pathophysiology, especially for those individuals who may have acomponent of vasculogenic dysfunction contributing to the overall femalesexual complaint. Aside from hormone replacement therapy, medicalmanagement of female sexual dysfunction remains in the early phases ofdevelopment. All non-hormonal medications listed below are undergoingsafety and efficacy testing for the treatment of male erectiledysfunction and are only in the experimental stage for the treatment offemale sexual dysfunction.

Estrogen replacement therapy is presently used in post-menopausal women(either spontaneous or surgical) for the treatment of hot flashes,prevention of osteoporosis, and diminishment of the risk of heartdisease. Estrogen replacement results in improved clitoral sensitivity,increased libido and decreased pain/burning during intercourse. Local ortopical estrogen application relieves symptoms of vaginal dryness,burning, urinary frequency and urgency. No clinical evidence exists thusfar that the use of topical estrogen cream results in relief of sexualcomplaints other than local vaginal pain or vaginal dryness.

Methyl testosterone may be used in combination with estrogen inpost-menopausal women for symptoms of inhibited desire, dyspareunia orlack of vaginal lubrication. Topical vaginal testosterone is used fortreatment of vaginal lichen planus. These women, usually elderly, arenoted to have clitoral enlargement, increased facial hair and increasedsexual appetite. There are conflicting reports regarding the benefit ofmethyl testosterone for the treatment of inhibited desire and/orvaginismus in pre-menopausal women.

In men, topical application of prostaglandin E1 combined with a skinenhancer such as SEPA is presently demonstrating initial success inpilot Phase II clinical trials. Clinical studies are necessary todetermine the safety and efficacy of this medication used as atopically-administered vaginal vasoactive agent in the treatment ofvasculogenic female dysfunction. However, one study has demonstratedincreased clitoral blood flow and clitoral erection following localprostaglandin E1 injection into clitoral corporal erectile tissues.

Sildenafil functions as a selective type 5 (i.e. c-GMP specific)phosphodiesterase inhibitor, and acts to decrease the metabolism ofc-GMP, the second messenger in nitric oxide mediated male erectileresponse. An oral formulation of this medication has proven to be safeand effective in improving erectile duration and rigidity. In females,nitric oxide/NOS exists in human vaginal and clitoral tissue. Sildenafilmay prove useful alone, or possibly in combination with other vasoactiveagents for the treatment of vasculogenic female sexual dysfunction.Clinical studies evaluating the efficacy of this medication in women areneeded.

Phentolamine is currently available as an oral preparation with rapidabsorption and metabolism. Phentolamine's mechanism of action.inducingvascular smooth muscle relaxation occurs via alpha-adrenergic blockadeas well as by direct smooth muscle relaxation. Studies are currently inprogress using this medication in women with female sexual dysfunction.

Despite these advances in the discovery of agents effective to treatfemale sexual dysfunction, there still exists a need for the discoveryof additional compounds useful in the treatment of this condition.

SUMMARY OF THE INVENTION

In one embodiment, the present invention provides a method of treatingor ameliorating sexual dysfunction in female mammals by administering toa mammal in need of such treatment a therapeutically effective amount ofa compound which acts upon mid-brain pathways to increase blood flow tothe ilio-hypogastric-pudendal arterial bed and genitalia.

In another embodiment, the present invention provides a method ofcombating vaginal pain by administering to a mammal in need of suchtreatment a therapeutically effective amount of a compound which actsupon mid-brain pathways to stimulate peripheral nerve release of nitricoxide (NO) in the pelvic nerve network, preferably from non-adrenergic,non-cholinergic (NANC) nerves. The vaginal pain may be generalhyperalgesia (non-specific increased vaginal sensitivity) or painassociated with intercourse (dyspareunia).

The selected compound is one which acts upon any of the mid-brainpathways which include the dopaminergic, serotonergic, oxytocinergic ornitroxidergic mid-brain pathways.

In another embodiment, the present invention provides a method forproducing an effective vasocongestive arousal in a female comprisingadministering a therapeutically effective amount of a compound whichacts upon a mid-brain dopaminergic, serotonergic, oxytocinergic ornitroxidergic pathway to increase blood flow to theilio-hypogastric-pudendal arterial bed and genitalia. By effectivevasocongestive arousal is meant clitoral erection, vaginal and labialarengorgement, and lubrication adequate for intercourse.

In yet another embodiment, the present invention provides a means oftreating vaginal engorgement insufficiency in a female mammal comprisingadministering a therapeutically effective amount of a compound whichacts upon a mid-brain dopaminergic, serotonergic, oxytocinergic ornitroxidergic pathway to increase blood flow to theilio-hypogastric-pudendal arterial bed and genitalia.

In another embodiment, the present invention provides a method oftreating clitoral erectile insufficiency in a female mammal comprisingadministering a therapeutically effective amount of a compound whichacts upon a mid-brain dopaminergic, serotonergic, oxytocinergic ornitroxidergic pathway to increase blood flow to theilio-hypogastric-pudendal arterial bed and genitalia.

In still another embodiment, the present invention comprises a method oftreating dyspareunia in a female mammal comprising administering atherapeutically effective amount of a compound which acts upon amid-brain dopaminergic, serotonergic, oxytocinergic or nitroxidergicpathway to facilitate peripheral nerve release of NO in the pelvic nervenetwork, preferably from non-adrenergic, non-cholinergic nerves.

In the embodiments described above, an androgen may optionally beco-administered with the primary active compound, whereinco-administration of the androgen enhances or potentiates the effect ofthe principal therapeutic agent.

In yet another embodiment, the present invention provides a means ofdiagnosing the presence or absence of sexual dysfunction in a femalemammal. The diagnostic method comprises the steps of administeringapomorphine alone or in combination with an androgen and observing anychange in physiologic response associated with sexual activity. A changeindicates the presence of sexual dysfunction.

BRIEF DESCRIPTION OF THE DRAWING

IN THE DRAWING:

FIG. 1 is a histogram depicting yawning response of female test animalsfollowing administration, in a first study, of various doses ofapomorphine.

FIG. 2 is a histogram depicting yawning response of female test animalsadministered, in a second study, equal 80 microgram/kg doses ofapomorphine at various times following the pre-administration of equal480 microgram/kg doses of testosterone.

FIG. 3 is a graph showing blood levels of estrogen and progesterone inthe female rat during various stages of the rat estrous cycle.

FIG. 4 is a histogram depicting genital licking and yawn response datafrom a third study in which female rats were administered either salineor 80 micrograms/kg of apomorphine during either the proestrus/estrus ormetestrus/diestrus stages of the estrous cycle.

FIG. 5 presents histograms depicting genital licking and yawn responsedata from a fourth study in which female rats were pre-administered 480microgram/kg doses of testosterone 36 hours prior to the administrationof saline or apomorphine during a particular stage of the estrous cycle.The data compare responses in the proestrus/estrus and themetestrus/diestrus stages following administration of testosterone andeither saline or apomorphine.

FIGS. 6 and 7 are histograms showing genital lick and yawn responsedata, respectively, from a study in which female rats were administeredeither saline or apomorphine, with or without the prior administrationof testosterone. Data are presented for both the proestrus/estrus andmetestrus/diestrus stages of the estrous cycle.

FIG. 8 is a histogram comparing genital lick and yawn response datawhich compare the data from the studies where either saline or an 80microgram/kg dose of. apomorphine was administered to test animals withand without prior administration of a 480 microgram/kg dose oftestosterone.

FIGS. 9 and 10 are histograms presenting genital lick and yawn responsedata, respectively, comparing intact animals administered control orsaline during the metestrus/diestrus stage of the rat estrous cycle withovariectomized animals administered a corresponding regimen of drug orcontrol.

DETAILED DESCRIPTION

As used throughout this specification and the appended claims, thefollowing terms have the meanings ascribed to them.

By “androgen” is meant any compound recognized in the art to elicit anandrogenic effect, either in their free base form or in the form of asalt or pro-drug by acting on androgen receptors in an agonist-likemanner. Also included in the definition of “androgen” is any compoundwhich mimics an art-recognized androgen, which compound stimulates oractivates androgenic pathways. Representative androgens includetestosterone, dihydrotestosterone (DHT), dehydro-epiandrostenedione(DHEA), and dehydroepiandrostenedione sulfate (DHEAS).

The terms “acute dose” or “acute administration” of a drug mean thescheduled administration of a drug to a patient on an as-needed basis ata dosage level determined by the attending physician to elicit arelatively immediate desired reaction in the patient, given thepatient's age and general state of health.

A “sub-acute dose” is a dose of the drug at a lower level than thatdetermined by the attending physician to be required for an acute dose,as described above. Sub-acute doses may be administered to the patienton an as-needed basis, or in a chronic, or on-going dosing regimen.

The terms “continuous dose” or “chronic administration” of a drug meanthe scheduled administration of a drug to the patient on an on-goingday-to-day basis.

The term “co-administration” of two or more drugs denotes thesimultaneous acute dosing of the drugs, or the sequential administrationof two or more drugs with a period of delay between theiradministration. One drug may be administered in a chronic dose, with theother drug(s) administered on an acute or as-needed basis.

By the term “treatment of sexual dysfunction” is meant the treatment,prevention, or amelioration of the conditions of delayed vaginalengorgement, diminished vaginal lubrication, pain or discomfort withintercourse (dyspareunia), diminished vaginal sensation, diminishedvaginal orgasm, diminished clitoral sensation, diminished clitoralorgasm, or generalized vaginal pain. In addition, the term “treatingsexual dysfunction,” as contemplated in this application, means theimprovement in a female of the physiological state associated withsexual activity which includes appropriate vaginal lubrication, vaginalsensation, vaginal orgasm, or clitoral sensation, but in whom one of theabove-mentioned abnormal conditions may not be present.

It is to be understood that the determination of the appropriate doseregimen for a given patient is well within the skill of the attendingphysician. Since the proper dose varies from person to person based onthe age and general state of health, it is a common practice ofphysicians to “dose-titrate” the patient; that is, to start the patienton a dosing regimen which is at a level below that required to producethe desired response, and gradually increase the dose until the desiredeffect is achieved.

The term “effective vasocongestive arousal” means, in the female,tumescent clitoral erection, engorgement, swelling and lubrication ofthe vagina and engorgement and swelling of the labia. Such arousalconditions may result from a net increase in blood flow to genitaltissues caused by (a) increased inflow with normal outflow, (b)increased inflow with decreased (vasoconstricted) outflow, or (c) normalinflow with decreased outflow.

Compounds useful in the methods of the present invention are thosecompounds which are known to act upon the mesencephalon or mid-brainnerve pathways to increase blood flow to the ilio-hypogastric-pudendalarterial bed and genitalia or to act on a mid-brain neural pathway tostimulate vasodilation, and genital engorgement and lubrication. Thisaction may be by, for example, peripheral release of nitric oxide (NO)from non-adrenergic, non-cholinergic (NANC) nerve cells in the pelvicregion. Examples of these compounds include those which are known to acton any of the dopaminergic, serotonergic, oxytocinergic or nitroxidergicmammalian mid-brain pathways to produce such peripheral effects.

Dopaminergic pathway compounds include apomorphine, bromocriptine,lisuride, methergoline, pergolide, piribidil, and quinpirole.

Serotonergic pathway compounds include serotonin receptor agonists suchas 1-(2,5-dimethoxy-4-iodophenyl)-laminopropane, 5-methoxytryptamine,a-methyl-5-hydroxytryptamine, 2-methyl-5-hydroxytryptamine,N-acetyl-5hydroxytryptamine buspirone, and sumatriptin. Oxytocinergicpathway compounds include oxytocin analogues such as isotocin,carbetocin, Lys-conopressin, deaminooxytocin, mesotocin, antocin,glumitocin, aspargitocin, valitocin, asvatocin, phasvatocin, andseritocin.

The preferred compound for use in the methods of the present inventionis apomorphine or one of its salts, esters or pro-drug forms.Apomorphine,(R)-5,6,6a,7-tetrahydro-6-methyl-(4H)-dibenzo[de,g]quinoline-10,11-diol,is a derivative of morphine obtained by treatment of the latter withconcentrated hydrochloric acid (L. Small, et al., J. Org. Chem., 5: 334(1940)) or by heating morphine with zinc chloride (Mayer, Ber., 4: 171(1871)). The compound has the chemical structure shown below andpossesses a chiral center at position 6a. The total synthesis of theracemic mixture is reported by J. L. Neumeyer, et al., J. Pharm. Sci.,59:1850 (1970) and the synthesis of the separate enantiomers by V. J.Ram and J. Neumeyer, J. Org. Chem., 46: 2830 (1981).

The compound possesses a basic nitrogen atom at position 6 and is thuscapable of existing in the free base form as well as acid addition saltforms. The compound may be administered as the free base or in the formof one of is its pharmaceutically acceptable salts or pro-drugderivatives.

As used herein, the term “pharmaceutically acceptable salt” refers tothose salts which are, within the scope of sound medical judgment,suitable for use in contact with the tissues of humans and lower animalswithout undue toxicity, irritation, allergic response and the like, andare commensurate with a reasonable benefit/risk ratio. Pharmaceuticallyacceptable salts are well known in the art. For example, S. M. Berge, etal. describe pharmaceutically acceptable salts in detail in J.Pharmaceutical Sciences, 66: 1-19 (1977). The salts are prepared in situduring the final isolation and purification of the compounds of theinvention, or separately by reacting the free base function with asuitable organic acid. Examples of pharmaceutically acceptable, nontoxicacid addition salts are salts of an amino group formed with inorganicacids such as hydrochloric acid, hydrobromic acid, phosphoric acid,sulfuric acid and perchloric acid or with organic acids such as aceticacid, oxalic acid, maleic acid, tartaric acid, citric acid, succinicacid or malonic acid or by using other methods used in the art such asion exchange. Other pharmaceutically acceptable salts include adipate,alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate,borate, butyrate, camphorate, camphorsulfonate, citrate,cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate,formate, fumarate, glucoheptonate, glycerophosphate, gluconate,hemisulfate, heptanoate, hexanoate, hydroiodide,2-hydroxy-ethanesulfonate, lactbbionate, lactate, laurate, laurylsulfate, malate, maleate, malonate, methanesulfonate,2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate,pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate,pivalate, propionate, stearate, succinate, sulfate, tartrate,thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and thelike.

The term “pro-drug” refers to compounds that are rapidly transformed invivo to yield the parent compound, as for example, by hydrolysis inblood. T. Higuchi and V. Stella provide a thorough discussion of thepro-drug concept in “Pro-drugs as Novel Delivery Systems”, Vol. 14 ofthe A.C.S. Symposium Series, American Chemical Society (1975). Examplesof esters useful as pro-drugs for compounds containing carboxyl groupsmay be found on pages 14-21 of “Bioreversible Carriers in Drug Design:Theory and Application,” edited by E. B. Roche, Pergamon Press (1987).

The term “pro-drug ester group” refers to any of several ester-forminggroups that are hydrolyzed under physiological conditions. Examples ofpro-drug ester groups include pivoyloxymethyl, acetoxymethyl,phthalidyl, indanyl and methoxymethyl, as well as other such groupsknown in the art.

As used herein, the term “pharmaceutically acceptable ester” refers toesters which hydrolyze in vivo and include those that break down readilyin the human body to leave the parent compound or a salt thereof.Suitable ester groups include, for example, those derived frompharmaceutically acceptable aliphatic carboxylic acids, particularlyalkanoic, alkenoic, cycloalkanoic and alkanedioic acids, in which eachalkyl or alkenyl moiety advantageously has not more than 6 carbon atoms.Examples of particular esters include formates, acetates, propionates,butryates, acrylates and ethylsuccinates.

Apomorphine has been shown to be effective in facilitating andmaintaining erectile response in males. Formulations containingapomorphine for this purpose, and methods of treating erectiledysfunction in males is disclosed in U.S. Pat. No. 5,770,606, the entirecontents of which are incorporated herein by reference.

The studies which are presented below illustrate that apomorphine alsoenhances the sexual response in females, with its effect beingpotentiated by co-administration of an androgen. The preferred androgenis testosterone or one of its pharmaceutically acceptable salts, estersor pro-drugs.

For an optimal vasocongestive arousal response in the female, steadystate circulating serum and mid-brain tissue levels of apomorphineshould be maintained within a relatively closely defined range. The drugis preferably administered in a formulation which delivers the drug tothe system while maintaining and not exceeding the desired systemiclevels of the drug. Methods known to the practitioner of thepharmaceutical formulation arts which accomplish this may be used. Forexample, the drug may be delivered to the system by means of a solidoral formulation, by a liquid formulation, including one appliedsub-lingually; by a tablet, lozenge, or lollipop held in the mouth andabsorbed buccally; by means of a suppository formulation administeredintravaginally or rectally; by a powder, gel, or suspension, or anintra-nasal spray formulation. Formulations for the intra-nasaladministration of apomorphine are taught, for example, in U.S. Pat. No.5,756,483 to Merkus; buccal or sub-lingual formulations for theadministration of apomorphine are taught in U.S. Pat. No. 5,888,534 toEl-Rashidy et al. The teachings of both patents are incorporatedherewith by reference.

The drug may also be administered in a sterile parenteral formulation bysub-cutaneous or intramuscular route, although sub-lingual, buccal,intra-nasal, and suppository formulations are preferred because of theirgreater ease of administration and the resulting greater potential forpatient acceptance.

Sublingual dosage forms, usually containing about 1 to about 12milligrams, preferably about 2.5 to about 10 milligrams of apomorphine,are useful in treating the symptoms of female vasculogenic sexualdysfunction, including its symptomatic manifestations without nausea orother undesirable side effects. Plasma concentrations of apomorphine arepreferably at between about 0.1 to 6 nanograms per milliliter,preferably between about 0.3 to about 4 nanograms per milliliter, andmore preferably between about 1 to about 2 nanograms per milliliter,sufficient to induce clitoral erection, vaginal and labialar engorgementand lubrication adequate for intercourse (i.e. “effective vasocongestivearousal”) but less than the amount that induces nausea.

The apomorphine is administered in the time period immediately prior tosexual activity, generally during the period between about 2 minutes and120 minutes prior to sexual activity, preferably during the periodbetween about 2 minutes and about 60 minutes prior to sexual activity,so as to achieve desired serum and mid-brain tissue levels of the drug.

Apomorphine has been recognized for use as an emetic when administeredsubcutaneously in about a 5-milligram dose. For the purposes of thepresent invention, apomorphine or a similarly acting dopamine receptoragonist is administered in an amount sufficient to excite cells in themid-brain region of the patient but with minimal side effects. This cellexcitation is believed to be part of a cascade of stimulation that islikely to include neurotransmission with serotonin and oxytocin.

The dopamine receptors in the mid-brain region of a patient can bestimulated to a degree sufficient to cause an erectile response by theadministration, preferably sublingually, of apomorphine so as tomaintain a plasma concentration of apomorphine of no more than about 5.5nanograms per milliliter (5.5 ng/ml). The sublingual administrationusually takes place over a time period in the range of aboutl to about10 minutes, or longer. The amount of apomorphine administeredsublingually over this time period is preferably in the range of about10 micrograms per kilogram (μg/kg) of body weight to about 100 μg/kg ofbody weight, more preferably from about 25 μg/kg to about 80 μg/kg ofbody weight.

Co-administration of an androgen potentiates the effect of apomorphinein eliciting sexual arousal, as shown in the studies described below.Representative suitable androgens for co-administration with apomorphinein the methods of the present invention include testosterone,dihydrotestosterone (DHT), dehydroepiandrostenedione (DHEA), andpharmaceutically acceptable salts, esters and pro-drugs of theforegoing, including testosterone undecanoate anddehydroepiandrostenedione sulfate(DHEAS).

The androgen is co-administered with the apomorphine, in one alternativedosing regimen, simultaneously, with both drugs being administered inacute doses, or with the apomorphine being administered in an acutedose, with the androgen administered in a sub-acute dose. Alternatively,the androgen may be administered at a chronic low dose, with theapomorphine administered in an as-needed dose, or with the apomorphineadministered chronically, with the androgen administered on an as-neededbasis.

Sustained release formulations for administration of a chronic low-doseof the androgen may take the form of well-known depot formulations,esters or pro-drugs which undergo bioconversion to release the androgen,or trans-dermal patch formulations.

In the studies shown below, the potentiating influence of an androgen onthe sexual arousal effects of apomorphine in female rats were found tobe maximal when the androgen was administered about thirty-six hoursprior to the administration of apomorphine. However, this delayed effectmay have been due to pharmacokinetic effects associated with the mode ofdelivery or the form of the drug employed. However, these data suggestthat slower-acting forms of androgen should be administered in theinterval between about 2 to about 48 hours prior to the administrationof apomorphine. The androgen may be made more readily available byadministration in a form which delivers the drug to the blood streammore rapidly. This can be achieved by direct application of the androgento mucosal tissue, such as by rectal, vaginal, intranasal, buccal, orsub-lingual administration. When a faster-acting form of androgen isemployed, the the androgen may be administered in the period 2-hoursprior to administration of the apomorphine, or concomitantly therewith.

In one alternative dosing regimen for co-administering an androgen andapomorphine to humans, the androgen is administered in an oral dosageform prior to the apomorphine, as in a pill, tablet, lozenge, or capsuleform. In a second alternative dosing regimen, the androgen isadministered in a rapidly-available form concomitantly with theapomorphine.

Andriol, (Organon, 375 Mt. Pleasant Ave., West Orange, N.J. 07.052) is arapidly available oral dosage form of testosterone undecanoate packagedas an oil solution sealed in capsules. This formulation rapidly deliverstestosterone by bypassing the liver and making the testosteroneavailable through the lymphatic system.

The present invention thus contemplates, in one embodiment, acombination package having unit dosage forms of both apomorphine and anandrogen, preferably testosterone. Both dosage forms may be in the formof rapidly acting doses of the two drugs, such as testosteroneundecanoate described above, and a buccal, sub-lingual, or intra-nasaldosage form of apomorphine.

Illustrative preferred sublingual dosage forms of apomorphine are setforth in Table I, below.

TABLE I 150-Milligram Apomorphine Hydrochloride Sublingual Tablets 3-mgTablet Apomorphine Hydrochloride 2.00 wt-% Mannitol 66.67 wt-% AscorbicAcid 3.33 wt-% Citric Acid 2.00 wt-% Avicel PH 102 15.00 Wt-% MethocelE4 10.00 Wt-% Aspartame 0.67 wt-% Magnesium stearate 0.33 wt-% 4-mgTablet Apomorphine Hydrochloride 2.66 wt-% Mannitol 66.00 wt-% AscorbicAcid 3.33 wt-% Citric Acid 2.00 wt-% Avicel PH102 15.00 wt-% MethocelE4M 10.00 Wt-% Aspartame 0.67 wt-% Magnesium stearate 0.33 wt-% 5-mgTablet Apomorphine Hydrochloride 3.33 wt-% Mannitol 65.34 wt-% AscorbicAcid 3.33 wt-% Citric Acid 2.00 wt-% Avicel PH102 15.00 wt-% MethocelE4M 10.00 wt-% Aspartame 0.67 wt-% Magnesium stearate 0.33 wt-%

If desired, and in order to facilitate absorption and thusbioavailability, the presently contemplated dosage forms can alsocontain, in addition to tableting excipients, β-cyclodextrin or aβ-cyclodextrin derivative such as hydroxypropyl-β-cyclodextrin (HPBCD).Illustrative dosage forms containing HPBCD are shown in Tables II andIII, below.

TABLE II Apomorphine Hydrochloride Sublingual Tablets WithHydroxypropyl- β-Cyclodextrin mg/Tab Apomorphine hydrochloride 4.0 HPBCD5.0 Ascorbic acid 10.0 PEG 8000 39.5 Mannitol 39.5 Aspartame 2.0 Total100.0

TABLE III Apomorphine Hydrochloride Sublingual Tablets Withβ-Cyclodextrin mg/Tab Apomorphine hydrochloride 5.0 β-Cyclodextrin 20.0Ascorbic acid 5.0 Mannitol 68.9 Magnesium stearate 1.0 D & C Yellow 10aluminum lake 0.1 TOTAL 100.0

The onset of nausea can be obviated or delayed by delivering apomorphineat a controlled dissolution rate so as to provide circulating serumlevels and midbrain tissue levels of apomorphine sufficient for aneffective vasocongestive arousal without inducing nausea. Whenapomorphine is administered at or near the relatively higher amounts ofthe aforementioned dosage range, the likelihood of nausea onset can bereduced by concurrent administration of a ganglionic agent (inhibitor ofganglionic response) such as nicotine or lobeline sulfate. For thispurpose, the weight ratio of apomorphine to ganglionic agent is in therange of about 10 to about 1.

Other antiemetic agents that can be used in conjunction with apomorphineare antidopaminergic agents such as metoclopramide, and thephenothiazines, e.g., chlorpromazine, prochlorperazine, pipamazine,thiethylperazine, oxypendyl hydrochloride, and the like. Also suitableare the serotonin (5-hydroxytryptamine or 5-HT) antagonists such asdomperidone, ondansetron (commercially available as the hydrochloridesalt under the designation Zofran©), and the like, the histamineantagonists such as buclizine hydrochloride, cyclizine hydrochloride,dimenhydrinate (Dramamine), and the like, the parasympatheticdepressants such as scopolamine, and the like, as well as otheranti-emetics such as metopimazine, trimethobenzamide, benzauinaminehydrochloride, diphenidol hydrochloride, and the like.

Nicotine-containing dosage forms and domperidone-containing dosage formsare illustrated in Table IV, below.

TABLE IV Apomorphine Hydrochloride Sublingual Tablets Containing anAnti-Emetic Agent mg/Tab Apomorphine hydrochloride 5.0 Ascorbic Acid 5.0Mannitol 67.9 Magnesium Stearate 1.0 Nicotine 1.0 β-Cyclodextrin 20.0 D& C Yellow aluminum lake 0.1 TOTAL 100.0 Apomorphine Hydrochloride 5.0Ascorbic Acid 5.0 Mannitol 58.9 Magnesium Stearate 1.0 Domperidone 10.0β-Cyclodextrin 20.0 D & C Yellow 10 aluminum lake 0.1 TOTAL 100.0

The preferred sublingual dosage forms dissolve within a time period ofat least about 2 minutes but less than about 10 minutes. The dissolutiontime can be longer, however, if desired as long as the desired plasmaconcentration of apomorphine can be achieved. More preferably, thedissolution time in water for the presently contemplated dosage forms isabout 3 minutes to about 5 minutes.

The present invention is illustrated further by the following studies.In the studies described below, the sexual behavior responses that werequantified were yawns and genital licks (the analogous female ratresponse to penile erections in the male rat). An event was counted as agenital lick when the animal stood on its hind legs, and rapidly anddecisively descended (with a concavity of the back) into the genitalarea and proceeded to lick it. The yawn response is a direct indicationof central activation of dopaminergic receptors by a drug (e.g.apomorphine). This pathway is at least in part convergent with thepathway which generates sexual responses. The yawns thereby represent asurrogate marker of sexual response. An event was counted as a yawn whenthe animal exhibited an involuntary opening of the mouth with theappropriate respiratory movement.

Female Wistar rats (Charles River Laboratories, (251 Ballardvale Street,Wilmington, Mass. 01887-1000, USA) utilized in the studies were housed,prior to each experiment, in plastic shoe-box cages in aclimate-controlled room with a 12-hour light/12-hour dark cycle. Therats were allowed free access to food and water except during times oftesting. During each test, the rats were placed in hanging cages fittedwith Plexiglas® bottoms, in a dark, quiet room where they were allowedto acclimate for 10 minutes. After this period either drug orphysiological saline (control) was injected subcutaneously to the backof the neck and subsequent genital licking and yawning responses wereobserved for 30 minutes from a separate room via a video monitoringsystem. The standard deviations for both types of responses wasdetermined, and statistical significance was determined using theStudent's t-test with p<0.05.

All experimental procedures were carried out in accordance with theguidelines established by the Canadian Council of Animal Care. Prior toany testing, each animal was handled by the investigator intermittentlyfor 5 days to allow for acclimation by the animals to handling.

A stock solution of apomorphine hydrochloride, containing the drug at aconcentration of 120 micrograms/mL, with 100 micrograms/mL of ascorbicacid in physiological saline, was prepared. The flask containing themixture was covered with foil paper to prevent any light-induceddecomposition and stored in refrigerator until used.

Testosterone propionate (Aldrich Chemical Co., Milwaukee, Wis., USA) wasdiluted from a stock solution of 100 mg/ml and dissolved in peanut oilprior to sub-cutaneous administration to animal.

In a first pilot study, randomized blind testing was performed withapomorphine doses of 40 micrograms/kg, 80 micrograms/kg, and 120micrograms/kg, using saline for control. Doses were obtained byadministering different amounts of the stock solution of 120micrograms/mL. The results are presented in FIGS. 1 and 2 where FIG. 1shows a dose-dependent yawning response in the test animals.

In a second study, the potentiating influence of an androgen,testosterone, on the effects of apomorphine on sexual response in femalerats was observed. Testosterone was administered at a dosage of 480micrograms/kg, with 80 microgram/kg doses of apomorphine beingsubsequently administered at times 0, 24, 36 and 48 hours followingadministration of the testosterone. The results are shown in FIG. 2where it was observed that the maximum number of apomorphine-inducedyawing responses were observed when apomorphine was administered 36hours following testosterone administration.

A third study was conducted to determine the effect of administeringapomorphine during the various stages of the female rat's estrous cycle.As shown in FIG. 3, the female rat's cycle is divided into 4 stagestotaling approximately 4 days: proestrus, estrus, metestrus anddiestrus. Estrogen levels are high prior to and at the beginning ofproestrus, while progesterone levels are high at the end of proestrus.Both of these hormones are at low levels in metestrus and most ofdiestrus. Estrogen and progesterone are suggested to exert their fullestinfluence not until at least 24 hours after secretion. As a consequence,estrogen exerts its fullest influence during the proestrus and estrusstages while progesterone exerts its maximum influence during themetestrus and early diestrus stages.

In this study, physiological saline solution or 80 microgram/kg doses ofapomorphine were sub-cutaneously administered to intact Wistar ratsduring either the proestrus/estrus stages or the metestrus/diestrusstages of their cycle. The stages for each animal were determined byexamining the epithelial cell type in vaginal smears after the method ofBaker, et al., “The Laboratory Rat”, Vols. 1-2, Academic Press, 1979.The observed licking and yawn response data are depicted in thehistograms appearing in FIG. 4. Apomorphine elicited a significantincrease (p<0.05) in yawns in the estrogen-influenced proestrus/estrusstages when compared with saline (control). However, no statisticallysignificant effect was seen over control in inducing yawns in theprogesterone influenced metestrus/diestrus stages. Apomorphine caused anincrease, albeit not statistically significant, in genital lickingresponses in the proestrus/estrus stages, but no observed differenceover control in the metestrus/diestrus stages.

In a fourth study, physiological saline solution (control) or 80microgram/kg doses of apomorphine were administered to intact femaleWistar rats during either the estrogen-influenced proestrus/estrusstages or the progesterone-influenced metestrus/diestrus stages,following prior administration of a 480 microgram/kg dose oftestosterone. The results of the second study had shown that thepotentiating influence of testosterone on the effects of apomorphinewere maximal at around 36 hours after testosterone administration. Thus,in this study, administration of apomorphine to a test animal was timedto fall into the proestrus/estrus stages or the metestrus/diestrusstages of the animal's cycle at the appropriate time followingadministration of testosterone.

The genital lick and yawn response data for this study are depictedgraphically in FIG. 5. The data show that testosterone pre-treatmentnormalized the licking response in the female rat regardless of thehormonal state of the animal, or whether it was apomorphine or salinethat was administered. However, testosterone pre-treatment increased theyawn responses in those animals to which apomorphine was administered,compared with those that received saline (control).

FIG. 6 depicts genital lick data comparing the administration of dosesof 80 microgram/kg doses of apomorphine or physiological saline solutionto two groups of intact Wistar rats to which testosterone was eitherpre-administered (striped bars) or not (open bars). The correspondingdata for yawn responses appears in FIG. 7.

Referring to FIG. 6, it can be seen that testosterone pre-treatmentincreased the observed number of genital licks in apomorphine-treatedanimals and saline-treated animals in the metestrus/diestrus stages whencompared to (a) animals treated with apomorphine and saline in theproestrus/estrus stages or (b) animals given no testosteronepre-treatment and apomorphine during the proestrus/estrus stages.

Referring to FIG. 7, pre-treatment of test animals with testosteronealso showed a larger increase over control in the number of observedyawn responses in apomorphine-treated animals during themetestrus/diestrus stages when compared to the increase over control intestosterone pre-treated animals given apomorphine during theproestrus/estrus stages.

To study the effect of testosterone pre-treatment in animals which hadconsiderably diminished levels of endogenous hormones, a fifth study wasconducted in which the prior experiments were repeated withovariectomized female Wistar rats. Rats were ovariectomized one monthprior to the experiments to ensure there was a minimal level ofendogenous hormones (estrogen and progesterone) present in the body.Ovariectomization involved the removal of the ovaries by severing thejunction between the fallopian tube and uterine horn after the methoddetailed by Waynforth, H. s and Flecknell, P., “Experimental andSurgical Technique in the Rat,” St. Edmundsbury Press, Ltd., 1992. Ratsthat underwent this procedure were given ketamine and xylazinepre-operatively as anesthetics and 2 doses of 0.1 mL of the antibioticTribrissen 24% (Schering Canada, Inc.) and Buprenex for post-operativeanalgesia respectively. The animals were pre-administered asub-cutaneous 480 microgram/kg dose of testosterone 36 hours prior tothe administration of physiological saline solution or an 80microgram/kg dose of apomorphine at the appropriate stage of the estrouscycle.

The genital lick and yawn response data for this experiment are showngraphically in FIG. 8. As can be seen in FIG. 8, the largest number ofgenital lick responses was seen in ovariectomized animals to which bothtestosterone and apomorphine had been administered. The effects ofapomorphine alone over control or apomorphine in combination withtestosterone over control in eliciting yawn responses is dramatic.

This study is informative with regard to the administration ofcombinations of testosterone and apomorphine to alleviate sexualdysfunction or normalize sexual function in post-menopausal women or inpre-menopausal women in which the hormonal milieu altered. The alteredlevels of endogenous hormones in such women are modeled by theovariectomized rat. The dramatic potentiating influence on the sexualarousal effects of co-administering androgen and apomorphine in theovariectomized rat strongly suggest the efficacy of the use of thiscombination in the treatment of post-menopausal women and pre-menopausalwomen in whom the hormonal milieu is altered. The present invention thusincludes the method of inducing effective vasocongestive arousal in suchwomen by co-administering a therapeutically effective dose ofapomorphine and an apomorphine-potentiating effective amount ofandrogen.

FIG. 9 depicts graphically a comparison of data for intact animalsadministered apomorphine (with and without testosterone pre-treatment)to ovariectomized animals administered apomorphine (with and withouttestosterone pre-treatment). The data for the intact animals is shownfor the metestrus/diestrus stages, since it is during these stages ofthe estrus cycle that endogenous hormonal levels are lowest in theintact animals, making for a fairer comparison with ovariectomizedanimals. As can be seen from FIG. 9, there was no significant differencein genital lick responses between ovariectomized and intact animals,with the exception that in the trial where the animals were administeredapomorphine alone.

FIG. 10 depicts graphically the corresponding yawn response datacomparing the intact and ovariectomized animals. The foregoing data showa marked increase in the apomorphine-treated ovariectomized animalscompared with intact animals. The same marked difference in yawnresponses in seen in the testosterone- and apomorphine-treated animals.

The foregoing data indicate that apomorphine is effective in initiatinga sexual response in female rats. Moreover, the studies show that thissexual response is highly dependent upon hormonal levels of estrogen,progesterone and testosterone, with estrogen and testosterone having apotentiating influence on the effect of apomorphine and progesteronehaving an inhibitory influence.

The foregoing discussion and the reported studies are intended asillustrative of the present invention and are not to be read as limitingthe invention as it is defined by the appended claims.

We claim:
 1. A method of treating sexual dysfunction in a female mammalin need of such treatment which comprises co-administering to saidfemale apomorphine or a pharmaceutically acceptable salt, ester, orpro-drug thereof, and an apomorphine-potentiating effective amount of anandrogen, such that sexual dysfunction is treated.
 2. The method ofclaim 1 wherein said androgen is selected from the group consisting oftestosterone, dihydro-testosterone (DHT), dehydroepiandrostenedione(DHEA), and pharmaceutically acceptable salts, esters and pro-drugsthereof.
 3. The method of claim 1 wherein said androgen is selected fromtestosterone and pharmaceutically acceptable salts, esters and pro-drugsthereof.
 4. The method of claim 1 wherein said androgen and saidapomorphine are chronically co-administered.
 5. The method of claim 1wherein said androgen and said apomorphine are co-administered on anas-needed basis.
 6. The method of claim 1 wherein said androgen isadministered prior to the administration of said apomorphine.
 7. Themethod of claim 6 wherein said androgen is administered from about 2hours to about 48 hours prior to the administration of said apomorphine.8. The method of claim 1 wherein said androgen is administeredconcomitantly with the administration of said apomorphine.
 9. The methodof claim 1 wherein said androgen and said apomorphine are administeredprior to sexual activity.
 10. The method of claim 9 wherein saidandrogen and said apomorphine are administered from about 2 minutes toabout 120 minutes prior to sexual activity.
 11. The method of claim 9wherein said apomorphine and said androgen are administered from about 2minutes to about 60 minutes prior to sexual activity.
 12. The method ofclaim 1 wherein at least one of said apomorphine and said androgen isadministered sublingually.
 13. The method of claim 12 wherein saidapomorphine or pharmaceutically acceptable salt, ester, or prodrugthereof is administered in an amount between about 1 milligram and about12 milligrams.
 14. The method of claim 12 wherein said apomorphine orpharmaceutically acceptable salt, ester, or prodrug thereof isadministered in an amount between about 2.5 milligrams and about 10milligrams.
 15. The method of claim 12 wherein said apomorphine orpharmaceutically acceptable salt, ester, or prodrug thereof isadministered in an amount between about 10 and about 100 micrograms perkilogram of body weight.
 16. The method of claim 12 wherein saidapomorphine or pharmaceutically acceptable salt, ester, or prodrugthereof is administered in an amount between about 25 and about 80micrograms per kilogram of body weight.
 17. The method of claim 12wherein the plasma concentration of apomorphine is maintained at a levelno more than about 5.5 nanograms per milliliter.
 18. The method of claim1 wherein the plasma concentration of apomorphine is maintained in therange of about 0.1 to about 6 nanograms per milliliter during sexualactivity.
 19. The method of claim 1 wherein the plasma concentration ofapomorphine is maintained in the range of about 0.3 to about 4 nanogramsper milliliter during sexual activity.
 20. The method of claim 1 whereinthe plasma concentration of apomorphine is maintained in the range ofabout 1 to about 2 nanograms per milliliter during sexual activity. 21.The method of claim 3 wherein said testosterone or pharmaceuticallyacceptable salt, ester or pro-drug thereof is administered in an amountof about 480 milligrams per kilogram of body weight.
 22. A method ofinducing effective vasocongestive arousal in a female mammal in need ofsuch treatment comprising co-administering to said female apomorphine ora pharmaceutically effective salt, ester, or pro-drug thereof, and anapomorphine-potentiating effective amount of an androgen, such thateffective vasocongestive arousal is induced.
 23. The method of claim 22wherein said apomorphine and said androgen are administered prior tosexual activity.
 24. The method of claim 22 wherein said androgen isselected from the group consisting of testosterone, dihydrotestosterone(DHT), dehydroepiandrostenedione (DHEA), and pharmaceutically acceptablesalts, esters and pro-drugs thereof.
 25. The method of claim 22 whereinsaid androgen is selected from testosterone and pharmaceuticallyacceptable salts, esters and pro-drugs thereof.
 26. The method of claim22 wherein said androgen is administered prior to the administration ofsaid apomorphine.
 27. The method of claim 22 wherein said androgen isadministered concomitantly with the administration of said apomorphine.28. The method of claim 22 wherein at least one of said apomorphine andsaid androgen is administered sublingually.
 29. A method of treatingvaginal engorgement insufficiency in a female mammal in need of suchtreatment comprising co-administering to said female apomorphine or apharmaceutically acceptable salt, ester or pro-drug thereof, and anapomorphine-potentiating effective amount of an androgen, such thatvaginal engorgement insufficiency is treated.
 30. The method of claim 29wherein said apomorphine and said androgen are administered prior tosexual activity.
 31. The method of claim 29 wherein said androgen isselected from the group consisting of testosterone, dihydrotestosterone(DHT), dehydroepiandrostenedione (DHEA), and pharmaceutically acceptablesalts, esters and pro-drugs thereof.
 32. The method of claim 29 whereinsaid androgen is selected from testosterone and pharmaceuticallyacceptable salts, esters and pro-drugs thereof.
 33. The method of claim29 wherein at least one of said apomorphine and said androgen isadministered sublingually.
 34. A method of treating clitoral erectileinsufficiency in a female mammal in need of such treatment comprisingco-administering to said female apomorphine or a pharmaceuticallyacceptable salt, ester or pro-drug thereof, and anapomorphine-potentiating effective amount of an androgen, such thatclitoral erectile insufficiency is treated.
 35. The method of claim 34wherein said apomorphine and said androgen are administered prior tosexual activity.
 36. The method of claim 34 wherein said androgen isselected from the group consisting of testosterone, dihydrotestosterone(DHT), dehydroepiandrostenedione (DHEA), and pharmaceutically acceptablesalts, esters and pro-drugs thereof.
 37. The method of claim 34 whereinsaid androgen is selected from testosterone and pharmaceuticallyacceptable salts, esters and pro-drugs thereof.
 38. The method of claim34 wherein at least one of said apomorphine and said androgen isadministered sublingually.
 39. A method of diagnosing sexual dysfunctionin a female patient comprising the steps of; a) administering to saidfemale apomorphine or a pharmaceutically acceptable salt, ester, orpro-drug thereof, and an apomorphine-potentiating effective amount of anandrogen; and b) assessing a change in the physiological response in thepatient to sexual activity, an improvement indicating sexual dysfunctionin said patient.
 40. The method of claim 39 wherein said androgen isselected from testosterone and a pharmaceutically effective salts,esters, and pro-drugs thereof.